PTC Therapeutics officer sells 2,494 shares

PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an automatic sale of 2,494 shares of common stock.

Rhea-AI Filing Summary

PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an automatic sale of 2,494 shares of common stock. The shares were sold at an average price of $69.36 per share to cover tax withholding obligations tied to recently vested restricted stock units.

These shares relate to the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. After this tax-withholding sale, Utter directly holds 70,199 shares of PTC Therapeutics common stock.

Insider Trade Summary

Net Seller: 2,494 shares

Net Sell 1 txn

Insider Utter Christine Marie

Role SVP, CHIEF ACCOUNTING OFFICER

Sold 2,494 shs ($173K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,494	$69.36	$173K

Holdings After Transaction: Common Stock — 70,199 shares (Direct)

Footnotes (1)

1. F1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and the vesting of 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTC Therapeutics (PTCT) report for Christine Marie Utter?

PTC Therapeutics reported that SVP and Chief Accounting Officer Christine Marie Utter sold 2,494 shares of common stock. The sale was automatically executed to cover tax withholding obligations arising from the vesting of restricted stock units granted on February 15, 2024.

How many PTC Therapeutics shares did Christine Marie Utter sell and at what price?

Christine Marie Utter sold 2,494 shares of PTC Therapeutics common stock at an average price of $69.36 per share. This transaction was reported as an automatic sale to satisfy tax withholding obligations linked to vesting restricted stock units.

Why were Christine Marie Utter’s PTC Therapeutics shares sold automatically?

The shares were sold automatically under an irrevocable sell-to-cover election to satisfy tax withholding obligations. These obligations arose from the vesting of 3,500 RSUs and 1,450 RSUs from two February 15, 2024 restricted stock unit grants to Christine Marie Utter.

How many PTC Therapeutics (PTCT) shares does Christine Marie Utter own after this transaction?

Following the tax-withholding sale, Christine Marie Utter directly owns 70,199 shares of PTC Therapeutics common stock. This remaining balance reflects her holdings after the automatic disposition of 2,494 shares to cover tax obligations from RSU vesting.

What RSU grants were involved in Christine Marie Utter’s tax-withholding sale at PTC Therapeutics?

The sale related to vesting from two February 15, 2024 RSU grants. One grant was for 14,000 RSUs, of which 3,500 vested, and the other for 2,900 RSUs, of which 1,450 vested, triggering associated tax withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Utter Christine Marie

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		2,494(1)	D	$69.36	70,199	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and the vesting of 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.